Gilead And Arcus Announced Etrumadenant Plus Zimberelimab, FOLFOX, And Bevacizumab Reduce Death Risk By 63% And Disease Progression by 73% vs Regorafenib In Phase 1b/2 Trial For Third-Line Metastatic Colorectal Cancer
Portfolio Pulse from Charles Gross
Gilead Sciences and Arcus Biosciences announced that their combination therapy significantly reduced the risk of death and disease progression in third-line metastatic colorectal cancer patients in a Phase 1b/2 trial. The results will be presented at the 2024 ASCO Annual Meeting.
June 02, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences announced positive Phase 1b/2 trial results for their mCRC therapy, showing significant reductions in death and disease progression risks.
The positive trial results for Gilead's mCRC therapy could boost investor confidence and potentially lead to increased stock prices due to the promising efficacy data.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Arcus Biosciences announced positive Phase 1b/2 trial results for their mCRC therapy, showing significant reductions in death and disease progression risks.
The positive trial results for Arcus's mCRC therapy could boost investor confidence and potentially lead to increased stock prices due to the promising efficacy data.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100